Skip to content
Home/Companies/Biotech/Calliditas
Calliditas

Calliditas

Biotech·Sweden·Exited 2024·Held 4yr
Entry
2020
Hold
4yr
Exit
2024

Who owns Calliditas?

Calliditas is a Swedish Biotech company, now owned by Asahi Kasei, which acquired it in 2024 from Sofinnova Partners.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
Sofinnova Partners
Investor
Sofinnova Partners
Sofinnova Crossover Fund I · 2018 · VC

Key facts

HQSweden
SectorBiotech
Websitewww.calliditas.se
Exit Type
Trade Sale
Buyer
Asahi Kasei
Exit Year
2024

More from Sofinnova Crossover Fund I

Other portfolio companies in the same fund.

GenSight Biologics
GenSight Biologics
Active
BiotechFrance
CellCentric
CellCentric
Active
BiotechUnited Kingdom· 2026
Amolyt Pharma
Amolyt Pharma
Exited 2024
BiotechFrance· 2021
to AstraZeneca
Sphere Bio (formerly Sphere Fluidics)
Sphere Bio (formerly Sphere Fluidics)
Exited 2025
MedTechUK· 2021
to Fluidic Analytics
Artios Pharma
Artios Pharma
Active
BiotechUK· 2020
Hemab Therapeutics
Hemab Therapeutics
Active
BiotechDenmark· 2020

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Calliditas?

Calliditas is now owned by Asahi Kasei, which acquired it in 2024 from Sofinnova Partners.

When did Asahi Kasei acquire Calliditas?

Asahi Kasei acquired Calliditas in 2024, buying from Sofinnova Partners.

Who did Calliditas sell to?

Sofinnova Partners sold Calliditas to Asahi Kasei in 2024 (Trade Sale).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue